New European patent approval for Episurf Medical
The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Method and node for manufacturing a surgical kit for cartilage repair”, covers the medical image segmentation process used for joint damage visualisation as well as for manufacturing of Episurf Medical’s patient-specific joint implants and surgical instruments.
"A comprehensive patent portfolio supporting various aspects of our technology has for a long time been a prioritised area, and this patent forms an important part thereof. This grant follows previous approvals for this patent family in China and Australia", comments Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.30 CET on 14 March 2018.